Next Article in Journal
Treatment of Lower Risk Myelodysplastic Syndromes
Next Article in Special Issue
From the Light Chain Sequence to the Tissue Microenvironment: Contribution of the Mesangial Cells to Glomerular Amyloidosis
Previous Article in Journal
The NKL- and TALE-Codes Represent Hematopoietic Gene Signatures to Evaluate Deregulated Homeobox Genes in Hodgkin Lymphoma
Previous Article in Special Issue
Monitoring Patients with Light Chain (AL) Amyloidosis during and after Therapy: Response Assessment and Identification of Relapse
 
 
Review
Peer-Review Record

Future Developments in the Treatment of AL Amyloidosis

Hemato 2022, 3(1), 131-152; https://doi.org/10.3390/hemato3010012
by Foteini Theodorakakou, Despina Fotiou, Meletios A. Dimopoulos and Efstathios Kastritis *
Reviewer 1: Anonymous
Reviewer 2: Anonymous
Reviewer 3: Anonymous
Hemato 2022, 3(1), 131-152; https://doi.org/10.3390/hemato3010012
Submission received: 19 November 2021 / Revised: 28 January 2022 / Accepted: 30 January 2022 / Published: 7 February 2022

Round 1

Reviewer 1 Report

This is a complete review of the literature currently available on the subject and provides some useful clinical pathways in the practical management of  AL Amyloidosis and highlighted the limits of current therapies in some subsets of patients

The literature reported includes the most recent studies about this issue and suggest potential strategies for optimal vaccine response.

Author Response

Thank you for your comments.

Reviewer 2 Report

The manuscript is fine, I only have two comments:

Authors should also mention rituximab and BTK inhibitors.

Please try to include a few more diagrams to illustrate the related signaling pathway in AL amyloidosis.

Author Response

Thank you for your comments

Comments 1: Response is included in the revised manuscript 

Comments 2: Kindly find in the attached Word two figures regarding signaling pathways in AL amyloidosis

Author Response File: Author Response.pdf

Reviewer 3 Report

Excellent review.

The paper still contains some spelling errors.
For example:

  • Intro line 3: from the clonal...
  • 2.4. cevostamabr instead of cevostamab
  • 2.5. Car instead of CAR-T

Author Response

Spelling errors have been corrected in the revised manuscript.

 

Thank you for your comments

Back to TopTop